|Videos|May 23, 2018

What Are Some of the Risk Factors for Augmented Renal Clearance?

Bruce A. Mueller, PharmD, explains the risk factors for augmented renal clearance.

Bruce A. Mueller, PharmD, professor of Clinical Pharmacy, University of Michigan College of Pharmacy explains the risk factors for augmented renal clearance.

Interview transcript (slightly edited for readability):

The other end of the spectrum is augmented renal clearance (ARC). They actually have a superhuman amount of GFR. For years, we’ve talked about, “Does this exist? Does this not exist?” Every once in a while, you would find some [data] that indicated maybe this is true. The fact of the matter is that there are a fair number of patients who have ARC. They have GFRs that are 250mL per minute (where the normal is maybe closer to 100). [As clinicians] we underappreciated this for years; however, there are patients in the intensive care unit (ICU) who have this and there have been studies that have looked at every patient who comes into the ICU, measuring actual creatinine clearance by urine, to see these patients’ GFRs. There is a substantial fraction of patients who have ARC. This has implications on drug clearance, and we may need to dose more aggressively for drugs that are renally eliminated.

Whether or not the presence of ARC has an impact on patient outcomes [is up in the air.] For every study that finds that it does, you can find another study that finds that it doesn’t. But, it stands to reason that if you are getting rid of antibiotics faster, and antibiotic serum concentrations may be lower, that’s a problem.

In terms of which patients would be at greatest risk of ARC; these patients will be younger (<50 years of age); patients who don’t have any other organ failure. If they are otherwise healthy individuals, but they have something that brings them into the surgical intensive care unit—which is the place we see a lot of ARC&mdash;you should have it in your mind, “I wonder what this patient’s GFR really is.” It might be worth performing something like a measured urine creatinine clearance, just to see if this might be a person in front of you who has a very rapid renal clearance, and maybe you need to dose your drugs differently.


Related to this article

This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Treatment of Latent Tuberculosis in a Trice
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.
Peggy Lillis Foundation Will Honor C diff Advocates at Annual Gala
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.